Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Trastuzumab cardiotoxiciy: the age-old balance of risk and benefit.

Ewer MS, Ewer SM.

Br J Cancer. 2016 Dec 6;115(12):1441-1442. doi: 10.1038/bjc.2016.381. No abstract available.

PMID:
27875521
2.

Trastuzumab-associated cardiac events in the Persephone trial.

Earl HM, Vallier AL, Dunn J, Loi S, Ogburn E, McAdam K, Hughes-Davies L, Harnett A, Abraham J, Wardley A, Cameron DA, Miles D, Gounaris I, Plummer C, Hiller L.

Br J Cancer. 2016 Dec 6;115(12):1462-1470. doi: 10.1038/bjc.2016.357.

PMID:
27875516
4.

Rationale and design of the multidisciplinary team IntervenTion in cArdio-oNcology study (TITAN).

Pituskin E, Haykowsky M, McNeely M, Mackey J, Chua N, Paterson I.

BMC Cancer. 2016 Sep 15;16(1):733. doi: 10.1186/s12885-016-2761-8.

5.

ErbB2 signaling at the crossing between heart failure and cancer.

Vermeulen Z, Segers VF, De Keulenaer GW.

Basic Res Cardiol. 2016 Nov;111(6):60. doi: 10.1007/s00395-016-0576-z. Review.

6.

Baseline Immunoglobulin E Levels as a Marker of Doxorubicin- and Trastuzumab-Associated Cardiac Dysfunction.

Beer LA, Kossenkov AV, Liu Q, Luning Prak E, Domchek S, Speicher DW, Ky B.

Circ Res. 2016 Oct 28;119(10):1135-1144.

PMID:
27582370
7.

Adjuvant systemic therapy in older women with breast cancer.

Leone J, Leone BA, Leone JP.

Breast Cancer (Dove Med Press). 2016 Jul 25;8:141-7. doi: 10.2147/BCTT.S110765. Review.

8.

Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.

Davis CC, Zelnak A, Eley JW, Goldstein DA, Switchenko JM, McKibbin T.

Ann Pharmacother. 2016 Sep;50(9):712-7. doi: 10.1177/1060028016654160.

9.

Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study.

Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K.

CMAJ Open. 2016 Feb 18;4(1):E66-72. doi: 10.9778/cmajo.20150033.

10.

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.

Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, Novo G, Pagliaro P, Pepe A, Tocchetti CG, Zito C, Mercuro G.

J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:S93-S104. doi: 10.2459/JCM.0000000000000383.

11.

Cardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged Sword.

Liu KL, Chen JS, Chen SC, Chu PH.

Acta Cardiol Sin. 2013 Jul;29(4):295-303. Review.

12.

Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.

Gavila J, Seguí MÁ, Calvo L, López T, Alonso JJ, Farto M, Sánchez-de la Rosa R.

Clin Transl Oncol. 2017 Jan;19(1):91-104. doi: 10.1007/s12094-016-1508-y.

13.

Adjuvant medical treatment for breast cancer in elderly and old women.

Westphal T, Rinnerthaler G, Mlineritsch B.

Memo. 2016;9:17-19. Review.

14.

Cardio-oncology: Concepts and practice.

Cubbon RM, Lyon AR.

Indian Heart J. 2016 Apr;68 Suppl 1:S77-85. doi: 10.1016/j.ihj.2016.01.022. Review.

15.

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.

Seferina SC, de Boer M, Derksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, Joore M, Peer PG, Voogd AC, Tjan-Heijnen VC.

Oncologist. 2016 May;21(5):555-62. doi: 10.1634/theoncologist.2015-0230.

PMID:
27009939
16.

The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis.

Wu YY, Huang TC, Tsai TN, Chen JH, Dai MS, Chang PY, Ho CL, Ye RH, Chung TR, Chen YC, Chao TY.

PLoS One. 2016 Mar 8;11(3):e0151112. doi: 10.1371/journal.pone.0151112.

17.

Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1.

Lucius K, Trukova K.

Integr Med (Encinitas). 2015 Aug;14(4):22-9. Review.

18.

Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.

Singh JC, Lichtman SM.

Drugs Aging. 2015 Dec;32(12):975-82. doi: 10.1007/s40266-015-0326-1.

19.

Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198).

Schneider BP, O'Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, Zander PJ, Davidson NE.

Br J Cancer. 2015 Dec 22;113(12):1651-7. doi: 10.1038/bjc.2015.405.

20.

Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.

Molinaro M, Ameri P, Marone G, Petretta M, Abete P, Di Lisa F, De Placido S, Bonaduce D, Tocchetti CG.

Biomed Res Int. 2015;2015:138148. doi: 10.1155/2015/138148. Review.

Items per page

Supplemental Content

Support Center